AQST
Price:
$4.56
Market Cap:
$415.77M
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2018-07-25
Stock Exchange
NASDAQ
Ticker
AQST
According to Aquestive Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -10.13. This represents a change of 0.47% compared to the average of -10.08 of the last 4 quarters.
The mean historical PE Ratio of Aquestive Therapeutics, Inc. over the last ten years is -12.73. The current -10.13 PE Ratio has changed 7.86% with respect to the historical average. Over the past ten years (40 quarters), AQST's PE Ratio was at its highest in in the March 2018 quarter at 19.58. The PE Ratio was at its lowest in in the March 2017 quarter at -55.08.
Average
-12.73
Median
-2.44
Minimum
-40.95
Maximum
-0.73
Discovering the peaks and valleys of Aquestive Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.05%
Maximum Annual PE Ratio = -0.73
Minimum Annual Increase = -94.07%
Minimum Annual PE Ratio = -40.95
Year | PE Ratio | Change |
---|---|---|
2023 | -15.72 | 2.05% |
2022 | -0.73 | -55.61% |
2021 | -1.65 | -40.27% |
2020 | -2.75 | 35.62% |
2019 | -2.03 | -4.53% |
2018 | -2.13 | -94.07% |
2017 | -35.89 | -12.35% |
The current PE Ratio of Aquestive Therapeutics, Inc. (AQST) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-6.03
5-year avg
-4.58
10-year avg
-12.73
Aquestive Therapeutics, Inc.’s PE Ratio is less than Evoke Pharma, Inc. (-0.99), less than Adamis Pharmaceuticals Corporation (-0.67), less than Guardion Health Sciences, Inc. (0.65), less than AcelRx Pharmaceuticals, Inc. (-2.52), less than Dynavax Technologies Corporation (79.53), less than Amphastar Pharmaceuticals, Inc. (14.01), less than Lantheus Holdings, Inc. (14.70), greater than ANI Pharmaceuticals, Inc. (-155.73), less than Ironwood Pharmaceuticals, Inc. (21.99), less than Alkermes plc (14.10), less than Eagle Pharmaceuticals, Inc. (0.34), less than Shuttle Pharmaceuticals Holdings, Inc. (-0.23), less than Mallinckrodt plc (-0.04), less than Agile Therapeutics, Inc. (-0.65), less than Lifecore Biomedical, Inc. (34.50), greater than Organogenesis Holdings Inc. (-72.75), less than Lucy Scientific Discovery Inc. (-1.23), greater than Alimera Sciences, Inc. (-20.50),
Company | PE Ratio | Market cap |
---|---|---|
-0.99 | $6.43M | |
-0.67 | $7.25M | |
0.65 | $4.35M | |
-2.52 | $14.58M | |
79.53 | $1.63B | |
14.01 | $2.19B | |
14.70 | $6.29B | |
-155.73 | $1.20B | |
21.99 | $550.50M | |
14.10 | $4.66B | |
0.34 | $12.31M | |
-0.23 | $3.19M | |
-0.04 | $4.52M | |
-0.65 | $10.43M | |
34.50 | $269.21M | |
-72.75 | $536.94M | |
-1.23 | $906.91K | |
-20.50 | $301.29M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aquestive Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aquestive Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Aquestive Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Aquestive Therapeutics, Inc. (AQST)?
What is the highest PE Ratio for Aquestive Therapeutics, Inc. (AQST)?
What is the 3-year average PE Ratio for Aquestive Therapeutics, Inc. (AQST)?
What is the 5-year average PE Ratio for Aquestive Therapeutics, Inc. (AQST)?
How does the current PE Ratio for Aquestive Therapeutics, Inc. (AQST) compare to its historical average?